Sign Up: Free Daily Tech E-letter  
Technology Home
Washtech
   -Companies
Tech Policy
Government IT
Markets
Columnists
Personal Tech
Special Reports
Jobs

Advertisement
Company Postings
Get Quotes
Press Releases
Tech Almanac

MedImmune Posts Loss in 2nd Quarter

Advertisement


E-Mail This Article
Print This Article
Permission to Republish
_____MedImmune, Inc._____
(MEDI) Stock Quote and News
Historical Chart
Company Description
Analyst Ratings
_____Local Tech News_____
Microsoft's 4th-Quarter Profit Rose 81% (The Washington Post, Jul 23, 2004)
A Nest for Fledgling Tech Firms (The Washington Post, Jul 22, 2004)
Revision to Criteria Reduces Number of Area Telecommuters (The Washington Post, Jul 22, 2004)
More Headlines
Tech Events Calendar
_____Post 200 Profile_____
MedImmune Inc.
_____MedImmune_____
Stock Quote and News
Historical Chart
Company Description
Analyst Ratings
_____Related Articles_____
MedImmune Posts $100 Million Loss in 2Q (Associated Press, Jul 22, 2004)
MedImmune To Try New FluMist Tactic (The Washington Post, Jun 16, 2004)
MedImmune Cuts Wyeth Tie (The Washington Post, Apr 28, 2004)
MedImmune, Wyeth End FluMist Partnership (The Washington Post, Apr 27, 2004)
More Company News
_____Earnings Watch_____
Volkswagen's Profit Drops, Issues Warning (Associated Press, Jul 23, 2004)
Halliburton Posts Loss on Charges (Reuters, Jul 23, 2004)
Xerox's 2Q Profit More Than Doubles (Associated Press, Jul 23, 2004)
Clear Channel Posts Profit, Ads Sluggish (Reuters, Jul 23, 2004)
Clear Channel Posts Profit, Radio Slow (Reuters, Jul 23, 2004)
More Earnings News
_____The Markets_____
Dow Over 12 Months
Nasdaq Over 12 Months
S&P 500 Over 12 Months
_____Biotech Headlines_____
A Flawed Formula (The Washington Post, Jul 22, 2004)
Hearing on Antidepressants Canceled (The Washington Post, Jul 21, 2004)
How Many Is Too Many? (The Washington Post, Jul 20, 2004)
More Biotech News
By Michael Barbaro
Washington Post Staff Writer
Friday, July 23, 2004; Page E05

MedImmune Inc. posted a loss in the second quarter largely because of the cost of dissolving a partnership with Wyeth to market the nasal-spray influenza vaccine FluMist, the company said yesterday.

The Gaithersburg biotechnology company lost $100 million (40 cents a share), compared with a profit of $13.5 million (5 cents) during the same period a year ago. Excluding charges associated with ending the Wyeth partnership, MedImmune lost $29 million, or 12 cents a share.

Revenue fell 17 percent, to $93.7 million. The company said second-quarter 2003 earnings included $30 million in non-product revenue, including one-time payments from Wyeth after FluMist was approved and from Abbott Laboratories after Synagis exceeded a sales milestone. Synagis, a treatment for infant lung infections, was developed by MedImmune and marketed with Abbott.

Product sales jumped 13 percent, to $91 million, driven primarily by higher demand for Synagis. Sales of the drug rose 10 percent. Sales of the cancer treatment Ethyol grew 4 percent, to $25 million, while sales of the infection treatment CytoGam more than doubled, to $8 million.

The company said the second-quarter results were significantly affected by sales of Synagis and FluMist, two seasonal drugs generally prescribed in the fall and winter.

Research and development costs rose 90 percent, to $57 million from $30 million, after the company initiated human tests for experimental drugs, including a new, non-frozen version of FluMist, which the company says should reach consumers by 2007. FluMist now must be stored in a freezer, which has hurt sales.

FluMist has so far flopped, selling fewer than 500,000 doses during its 2003 debut. The company said it does not expect the vaccine to generate significant revenue until the new version is approved.

For now, MedImmune is cutting FluMist's price by nearly half, to $23.50, ditching its consumer marketing campaign and focusing on winning over skeptical doctors. In April, MedImmune ended its marketing agreement with Wyeth and predicted the decision would cost it $105 million.

For the third quarter, the company forecast a loss of between 26 cents and 29 cents a share and revenue of between $85 million and $90 million.

Shares of MedImmune closed yesterday at $23.18, up 68 cents, or about 3 percent.


TechNews.com Home

© 2004 The Washington Post Company

Company Postings: Quick Quotes | Tech Almanac
About TechNews.com | Advertising | Contact TechNews.com | Privacy
My Profile | Rights & Permissions | Subscribe to print edition | Syndication